Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain

Yossef Itzhak, Syed F. Ali

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Although the alkaloid ibogaine is a potent hallucinogenic agent some indications suggest that it may be useful for the treatment of opioid and cocaine addiction. The neurochemical mechanism(s) underlying ibogaine effects remain unclear. In the present study we investigated the interaction of ibogaine with the phencyclidine (PCP) site located in the ionophore of the N-methyl-D-aspartate (NMDA) receptor complex, with the NMDA receptor binding site, and with sigma binding sites. In well-washed membrane preparations of rat cortex and cerebellum, the PCP sites were labeled with [3H]MK-801 or [3H]1-[1(2-theinyl)-cyclohexyl]-piperidine ([3H]TCP), and the NMDA receptor with [3H]-CGP 39653. The sigma-1 and sigma-2 binding site in rat cortex and cerebellum were labeled with [3H]pentazocine and [3H]1,3-di-o-tolyl-guanidine ([3H]DTG), respectively. Results indicated that ibogaine interacts with high- and low-affinity PCP binding sites in the cortex: K(i)(H) = 0.01-0.05 μM; K(i)(L) = 2-4 μM, and only with low-affinity sites in the cerebellum: K(i) = 2-4, μM. In contrast, ibogaine (> 100 μM) had no affinity for [3H]-CGP 39653 binding sites (cortex and cerebellum). The affinity of ibogaine for sigma-1 and -2 binding sites in cortex and cerebellum ranged from 1.5-3 μM. Since NMDA receptor antagonists (e.g., MK-801) are thought to attenuate opioid withdrawal symptoms and cocaine sensitization, it is possible that binding of ibogaine to the PCP sites contributes to its potential 'endabuse' properties. In turn, ibogaine interaction with sigma binding sites may be associated with its adverse effects.

Original languageEnglish
Pages (from-to)245-251
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume844
DOIs
StatePublished - Aug 19 1998

Fingerprint

Ibogaine
N-Methyl-D-Aspartate Receptors
Rats
Brain
Binding Sites
Cerebellum
Dizocilpine Maleate
Cocaine
Opioid Analgesics
Hallucinogens
Pentazocine
Rat
Phencyclidine
Cocaine-Related Disorders
Substance Withdrawal Syndrome
Ionophores
Guanidine
Alkaloids

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain. / Itzhak, Yossef; Ali, Syed F.

In: Annals of the New York Academy of Sciences, Vol. 844, 19.08.1998, p. 245-251.

Research output: Contribution to journalArticle

@article{6c375e5dc5a649db90463ee705a25290,
title = "Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain",
abstract = "Although the alkaloid ibogaine is a potent hallucinogenic agent some indications suggest that it may be useful for the treatment of opioid and cocaine addiction. The neurochemical mechanism(s) underlying ibogaine effects remain unclear. In the present study we investigated the interaction of ibogaine with the phencyclidine (PCP) site located in the ionophore of the N-methyl-D-aspartate (NMDA) receptor complex, with the NMDA receptor binding site, and with sigma binding sites. In well-washed membrane preparations of rat cortex and cerebellum, the PCP sites were labeled with [3H]MK-801 or [3H]1-[1(2-theinyl)-cyclohexyl]-piperidine ([3H]TCP), and the NMDA receptor with [3H]-CGP 39653. The sigma-1 and sigma-2 binding site in rat cortex and cerebellum were labeled with [3H]pentazocine and [3H]1,3-di-o-tolyl-guanidine ([3H]DTG), respectively. Results indicated that ibogaine interacts with high- and low-affinity PCP binding sites in the cortex: K(i)(H) = 0.01-0.05 μM; K(i)(L) = 2-4 μM, and only with low-affinity sites in the cerebellum: K(i) = 2-4, μM. In contrast, ibogaine (> 100 μM) had no affinity for [3H]-CGP 39653 binding sites (cortex and cerebellum). The affinity of ibogaine for sigma-1 and -2 binding sites in cortex and cerebellum ranged from 1.5-3 μM. Since NMDA receptor antagonists (e.g., MK-801) are thought to attenuate opioid withdrawal symptoms and cocaine sensitization, it is possible that binding of ibogaine to the PCP sites contributes to its potential 'endabuse' properties. In turn, ibogaine interaction with sigma binding sites may be associated with its adverse effects.",
author = "Yossef Itzhak and Ali, {Syed F.}",
year = "1998",
month = "8",
day = "19",
doi = "10.1111/j.1749-6632.1998.tb08239.x",
language = "English",
volume = "844",
pages = "245--251",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain

AU - Itzhak, Yossef

AU - Ali, Syed F.

PY - 1998/8/19

Y1 - 1998/8/19

N2 - Although the alkaloid ibogaine is a potent hallucinogenic agent some indications suggest that it may be useful for the treatment of opioid and cocaine addiction. The neurochemical mechanism(s) underlying ibogaine effects remain unclear. In the present study we investigated the interaction of ibogaine with the phencyclidine (PCP) site located in the ionophore of the N-methyl-D-aspartate (NMDA) receptor complex, with the NMDA receptor binding site, and with sigma binding sites. In well-washed membrane preparations of rat cortex and cerebellum, the PCP sites were labeled with [3H]MK-801 or [3H]1-[1(2-theinyl)-cyclohexyl]-piperidine ([3H]TCP), and the NMDA receptor with [3H]-CGP 39653. The sigma-1 and sigma-2 binding site in rat cortex and cerebellum were labeled with [3H]pentazocine and [3H]1,3-di-o-tolyl-guanidine ([3H]DTG), respectively. Results indicated that ibogaine interacts with high- and low-affinity PCP binding sites in the cortex: K(i)(H) = 0.01-0.05 μM; K(i)(L) = 2-4 μM, and only with low-affinity sites in the cerebellum: K(i) = 2-4, μM. In contrast, ibogaine (> 100 μM) had no affinity for [3H]-CGP 39653 binding sites (cortex and cerebellum). The affinity of ibogaine for sigma-1 and -2 binding sites in cortex and cerebellum ranged from 1.5-3 μM. Since NMDA receptor antagonists (e.g., MK-801) are thought to attenuate opioid withdrawal symptoms and cocaine sensitization, it is possible that binding of ibogaine to the PCP sites contributes to its potential 'endabuse' properties. In turn, ibogaine interaction with sigma binding sites may be associated with its adverse effects.

AB - Although the alkaloid ibogaine is a potent hallucinogenic agent some indications suggest that it may be useful for the treatment of opioid and cocaine addiction. The neurochemical mechanism(s) underlying ibogaine effects remain unclear. In the present study we investigated the interaction of ibogaine with the phencyclidine (PCP) site located in the ionophore of the N-methyl-D-aspartate (NMDA) receptor complex, with the NMDA receptor binding site, and with sigma binding sites. In well-washed membrane preparations of rat cortex and cerebellum, the PCP sites were labeled with [3H]MK-801 or [3H]1-[1(2-theinyl)-cyclohexyl]-piperidine ([3H]TCP), and the NMDA receptor with [3H]-CGP 39653. The sigma-1 and sigma-2 binding site in rat cortex and cerebellum were labeled with [3H]pentazocine and [3H]1,3-di-o-tolyl-guanidine ([3H]DTG), respectively. Results indicated that ibogaine interacts with high- and low-affinity PCP binding sites in the cortex: K(i)(H) = 0.01-0.05 μM; K(i)(L) = 2-4 μM, and only with low-affinity sites in the cerebellum: K(i) = 2-4, μM. In contrast, ibogaine (> 100 μM) had no affinity for [3H]-CGP 39653 binding sites (cortex and cerebellum). The affinity of ibogaine for sigma-1 and -2 binding sites in cortex and cerebellum ranged from 1.5-3 μM. Since NMDA receptor antagonists (e.g., MK-801) are thought to attenuate opioid withdrawal symptoms and cocaine sensitization, it is possible that binding of ibogaine to the PCP sites contributes to its potential 'endabuse' properties. In turn, ibogaine interaction with sigma binding sites may be associated with its adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=0031868647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031868647&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.1998.tb08239.x

DO - 10.1111/j.1749-6632.1998.tb08239.x

M3 - Article

C2 - 9668682

AN - SCOPUS:0031868647

VL - 844

SP - 245

EP - 251

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -